Browse > Article

Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia  

Zhang, Gui-Fang (Department of Hematology, First People's Hospital of Changshu)
Zhou, Min (Department of Hematology, First People's Hospital of Changshu)
Bao, Xie-Bing (Leukemia Research Division, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, First Affiliated Hospital of Soochow University)
Qiu, Hui-Ying (Leukemia Research Division, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, First Affiliated Hospital of Soochow University)
Li, Zheng (Leukemia Research Division, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, First Affiliated Hospital of Soochow University)
Xue, Sheng-Li (Leukemia Research Division, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, First Affiliated Hospital of Soochow University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.9, 2016 , pp. 4477-4481 More about this Journal
Abstract
Purpose: To compare the relative merits of imatinib and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelogenous leukemia (CML). Materials and Methods: This cohort study was designed to compare the outcomes of imatinib (n=292) versus allo-HSCT (n=141) for CML, the clinical data of these patients being retrospectively analyzed so as to compare the event free survival (EFS) and overall survival (OS) between these two groups with patients in the chronic phase (CP) and advanced phases, including accelerate (AP) and blast phases (BP). Results: (1) Patients treated with imatinib (278 in the CP) demonstrated superior EFS, OS, 5-year EFS and 5-year OS rates of 88.5% versus 70.0% (P<0.05), 93.2% versus 80.0% (P<0.05), 84% versus 75.0% (P<0.05) and 92% versus 79.0% (P<0.05), respectively, to those treated with allo-HSCT (120 patients in the CP). (2) Both treatments resulted in similar survival, with EFS and OS rates of 42.9% versus 47.6% (P>0.05), 42.9% versus 57.1% (P> 0.05), respectively, for imatinib (14 patients in the AP and BP) and allo-HSCT (21 patients in the AP and BP). Conclusions: Imatinib confers significant survival advantage (EFS and OS) for CML patients with CP compared with allo-HSCT treatment. However, the outcomes are equally good with both treatments in AP and BP patients.
Keywords
Chronic myelogenous leukemia; imatinib; allogeneic stem cell transplantation; survival analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hehlmann R, Berger U, Pfirrmann M, et al (2007). Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 109, 4686-92.   DOI
2 Hochhaus A, O'Brien SG, Guilhot F, et al (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23, 1054-61.   DOI
3 Jabbour E (2016). Chronic myeloid leukemia, First-line drug of choice. Am J Hematol, 91, 59-66.   DOI
4 Jabbour E, Kantarjian H, Jones D, et al (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 112, 53-5.   DOI
5 Jiang Q, Xu LP, Liu DH, et al (2011). Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood, 117, 3032-40.   DOI
6 Jiang Q, Zhao D, Jin J, et al (2015). A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi, 36, 651-5.
7 Kujak C, Kolesar JM (2016). Treatment of chronic myelogenous leukemia. Am J Health Syst Pharm, 73, 113-20.   DOI
8 Moslehi JJ, Deininger M (2015). Tyrosine kinase inhibitorassociated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol, 33, 4210-8.   DOI
9 Nair AP, Barnett MJ, Broady RC, et al (2015). Allogeneic hematopoietic stem cell transplantation is an effective salvage therapy for patients with chronicmyeloid leukemia presenting with advanced disease or failing treatment with tyrosine kinase inhibitors. Biol Blood Marrow Transplant, 21, 1437-44.   DOI
10 Baccarani M, Saglio G, Goldman J, et al (2006). Evolving concepts in the management of chronic myeloid leukemia, recommendations from an expert panel on behalf of the European LeukemiaNe. Blood, 108, 1809-20.   DOI
11 Barrett AJ, Ito S (2015). The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood, 125, 3230-5.   DOI
12 Castagnetti F, Gugliotta G, Breccia M, et al (2015). Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia, 29, 1823-31.   DOI
13 Cortes J, Jabbour E, Kantarjian H, et al (2007). Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 110, 4005-11.   DOI
14 Firwana B, Sonbol MB, Diab M, et al (2016). Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia inchronic phase, A mixed-treatment comparison. Int J Cancer, 138, 1545-53.   DOI
15 Goldman JM, Melo JF (2003). Chronic myeloid leukemia advances in biology and new approaches to treatment. N Engl J Med, 349, 1461-64.
16 Gratwohl A, Brand R, Apperley J, et al (2006). Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006, transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 91, 513-21.
17 Gratwohl A, Heim D (2009). Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol, 22, 431-43.   DOI
18 Ruiz-Cordell K, Haimowitz S, Gracie-King L, et al (2016). Optimizing the use of TKIs in the management of chronic myelogenous leukemia. Clin Lymphoma Myeloma Leuk, 16, 442-6.   DOI
19 O'Brien S, Radich JP, Abboud CN, et al (2014).Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw, 12, 1590-610.   DOI
20 Pagnano KB, Bendit I, Boquimpani C, et al (2015). BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival. Cancer Invest, 33, 451-8.   DOI
21 Sasaki K, Kantarjian HM, Jain P, et al (2016). Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer, 122, 238-48.   DOI
22 Saussele S, Lauseker M, Gratwohl A, et al (2010). Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era, evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 115, 1880-5.   DOI
23 Schiffer CA (2007). BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med, 357, 258-65.   DOI
24 Thompson PA, Kantarjian HM, Cortes JE (2015). Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc, 90, 1440-54.   DOI
25 Xu L, Zhu H, Hu J, et al (2015). Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. JOURNAL??, 9, 304-11.   DOI